Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection

[1]  T. Roskams,et al.  EASL clinical practical guidelines: management of alcoholic liver disease. , 2012, Journal of hepatology.

[2]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[3]  R. Fontana,et al.  Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[4]  M. Tonelli,et al.  Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Scott Bowden,et al.  Drug resistance in antiviral therapy. , 2010, Clinics in liver disease.

[6]  R. Schooley,et al.  Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop , 2010, The American Journal of Gastroenterology.

[7]  R. Gish,et al.  1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB) , 2010 .

[8]  R. Fontana.  Side effects of long‐term oral antiviral therapy for hepatitis B , 2009, Hepatology.

[9]  Y. Liaw,et al.  Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) , 2008 .

[10]  Ling-xia Zhang,et al.  [AASLD practice guidelines: chronic hepatitis B]. , 2007, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[11]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.